Publications by authors named "R Sinvhal"
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil.
An Bras Dermatol
December 2024
Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit.
Objective: The authors assessed the efficacy and safety of risankizumab compared with methotrexate in adults with moderate-to-severe plaque psoriasis.
Article Synopsis
- The study examines the effectiveness and safety of risankizumab for treating moderate-to-severe plaque psoriasis, focusing on racial and ethnic disparities in diagnosis and representation in clinical trials.
- A total of 897 patients participated, with significant reductions in psoriasis severity and improvements in quality of life reported, particularly among Black or African American and Hispanic or Latino patients.
- Results suggest that risankizumab shows similar efficacy across different racial and ethnic groups without any new safety concerns arising during the treatment.
Introduction: Risankizumab has demonstrated a favourable safety profile in patients with psoriatic disease (moderate-to-severe psoriasis [PsO] and psoriatic arthritis [PsA]). We evaluated the long-term safety of risankizumab in psoriatic disease.
Methods: Long-term safety was evaluated by analysing data from 20 (phase 1-4) clinical trials for plaque PsO and four (phase 2-3) trials for PsA.
Background: Psoriasis is a chronic, inflammatory skin disease often requiring long-term therapy.
Objective: To evaluate the long-term safety and efficacy of risankizumab in patients with psoriasis.
Methods: LIMMitless is an ongoing phase 3, open-label extension study evaluating the long-term safety and efficacy of continuous risankizumab 150 mg every 12 weeks for adults with moderate-to-severe plaque psoriasis following multiple phase 2/3 base studies.